Evidence map›Paper›PMID 27379206›Full record

ArticleFrontiers in oncology2016

Hypoxia on the Expression of Hepatoma Upregulated Protein in Prostate Cancer Cells.

Ingrid Espinoza, Marcelo J Sakiyama, Tangeng Ma, Logan Fair, Xinchun Zhou, Mohamed Hassan, Jovanny Zabaleta, Christian R Gomez

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Ingrid EspinozaCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA; Department of Preventive Medicine, University of Mississippi Medical Center, Jackson, MS, USA; Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS, USA.
Marcelo J SakiyamaCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA; Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA; CAPES Foundation, Ministry of Education of Brazil, Brasília, Brazil.
Tangeng MaCancer Institute, University of Mississippi Medical Center , Jackson, MS , USA.
Logan FairSchool of Medicine, University of Mississippi Medical Center , Jackson, MS , USA.
Xinchun ZhouDepartment of Pathology, University of Mississippi Medical Center , Jackson, MS , USA.
Mohamed HassanCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA; Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA.
Jovanny ZabaletaStanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Christian R GomezCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA; Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA; Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
Jackson Memorial Hospital · USUniversity of Mississippi Medical Center · USLouisiana State University Health Sciences Center New Orleans · USMinistry of Education · BR

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Molecular and Soc. Determinants of Obesity and Metabolic Disorders in YouthU54MD008176 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BASKIN, MONICA L. · 2012 to 2016
$13.7M
Mentoring Translational Researchers in LouisianaP20GM103501 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2012 to 2014
$6.3M
Training CoreP20MD004817 · NIMHD · DILLARD UNIVERSITY · PI JONES, WARREN ALLEN · 2010 to 2014
$6.3M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
NIGMS NIH HHS P20 GM103501NIGMS NIH HHS P30 GM114732NIGMS NIH HHS U54 GM104940NIMHD NIH HHS P20 MD004817NIMHD NIH HHS U54 MD008176
6 · The paper itself

Abstract

Hepatoma upregulated protein (HURP) is a multifunctional protein with clinical promise. This protein has been demonstrated to be a predictive marker for the outcome in high-risk prostate cancer (PCa) patients, besides being a resistance factor in PCa. Although changes in oxygen tension (pO2) are associated with PCa aggressiveness, the role of hypoxia in the regulation of tumor progression genes such as HURP has not yet been described. We hypothesized that pO2 alteration is involved in the regulation of HURP expression in PCa cells. In the present study, PCa cells were incubated at 2% O2 (hypoxia) and 20% O2 (normoxia) conditions. Hypoxia reduced cell growth rate of PCa cells, when compared to the growth rate of cells cultured under normoxia (p < 0.05). The decrease in cell viability was accompanied by fivefold (p < 0.05) elevated rate of vascular endothelial growth factor (VEGF) release. The expression of VEGF and the hypoxia-inducible metabolic enzyme carbonic anhydrase 9 were elevated maximally nearly 61-fold and 200-fold, respectively (p < 0.05). Noted in two cell lines (LNCaP and C4-2B) and independent of the oxygen levels, HURP expression assessed at both mRNA and protein levels was reduced. However, the decrease was more pronounced in cells cultured under hypoxia (p < 0.05). Interestingly, the analysis of patients' specimens by Western blot revealed a marked increase of HURP protein (fivefold), when compared to control (cystoprostatectomy) tissue (p < 0.05). Immunohistochemistry analysis showed an increase in the immunostaining intensity of HURP and the hypoxia-sensitive molecules, hypoxia-inducible factor 1-alpha (HIF-1α), VEGF, and heat-shock protein 60 (HSP60) in association with tumor grade. The data also suggested a redistribution of subcellular localization for HURP and HIF-1α from the nucleus to the cytoplasmic compartment in relation to increasing tumor grade. Analysis of HURP Promoter for HIF-1-binding sites revealed presence of four putative HIF binding sites on the promoter of DLGAP5/HURP gene in the non-translated region upstream from the start codon, suggesting association between HIF-1α and the regulation of HURP protein. Taken together, our findings suggest a modulatory role of hypoxia on the expression of HURP. Additionally our results provide basis for utilization of tumor-associated molecules as predictors of aggressive PCa.

Indexed as

C4-2BHURPhypoxiaLNCaPprostate cancertumor

Identifiers

PMID27379206
PMCPMC4908134
OpenAlexW2438968589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.